CEP
NEO icon

Chicago Equity Partners’s NeoGenomics NEO Stock Holding History

Chicago Equity Partners’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-12,850
Closed -$376K – 798
2019
Q4 		$376K Buy
+12,850
New +$306K 0.02% 703

Other funds holding NEO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KFO
Kopp Family Office Bloomington, Minnesota $163M AUM 22.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Chicago Equity Partners's NEO Position: Q1 2020 in Review

Chicago Equity Partners sold out of NeoGenomics (NEO) in Q1 2020, closing a stake of 12,850 shares — an estimated $376K sold.

Chicago Equity Partners first reported a position in NEO in Q4 2019 and held it in 1 quarter. The position peaked at $376K in Q4 2019. 272 funds tracked by Wall St. Rank hold NEO as of Q1 2020.

  • Chicago Equity Partners reported no remaining NeoGenomics position as of Q1 2020 after selling out during the quarter.
  • Chicago Equity Partners sold 12,850 NeoGenomics shares in Q1 2020, an estimated $376K.
  • Chicago Equity Partners first reported a position in NeoGenomics in Q4 2019 and held it in 1 quarter.
  • Chicago Equity Partners's NeoGenomics position peaked at $376K in Q4 2019.
  • 272 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.